Trial	Stage	Intervention after surgery	Estimated enrollment	Primary endpoint
ANVIL	IB-IIIA	Arm A: optional CT and RT nivolumab 1 year Arm B: optional CT and RT → observation	903	DFS OS
PEARLS/KEYNOTE-091	IB-IIIA	Arm A: optional CT → pembrolizumab 1 year Arm B: optional CT → placebo	1080	DFS
BR31	IB-IIIA	Arm A: optional CT (+ optional RT if N2) → durvalumab 1 year Arm B: optional CT (+ optional RT if N2) → placebo	1360	DFS
ALCHEMIST	IB-IIIA	Arm A: CT Arm B: CT à pembrolizumab Arm C: CT + pembrolizumab → pembrolizumab	1263	DFS OS
MEMAID-1	II-IIIA	Arm A: Durvalumab + CT for MRD (+) Arm B: Placebo + CT for MRD (+)	332	DFS
MERMAID-2	II-IIIA	Arm A: Durvalumab for MRD (+) after CT Arm B: Placebo for MRD (+) after CT	284	DFS for PD-L1 ≥ 1%